Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERT-HF: Vericiguat in HFrEF with Severe TR and Right Heart Failure
NCT07668739Phase 4Not yet recruiting
- Sponsor
- Daejeon St. Mary's Hospital
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 4 trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF), tricuspid regurgitation, right-sided heart failure, sponsored by Daejeon St. Mary's Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)tricuspid regurgitationright-sided heart failure
Beyond the preview
Go deeper on NCT07668739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668739.